Published in Addiction on November 01, 2009
EASE Guidelines for Authors and Translators of Scientific Articles to be Published in English: European Association of Science Editors (EASE). J Tehran Heart Cent (2011) 2.43
Public health, academic medicine, and the alcohol industry's corporate social responsibility activities. Am J Public Health (2012) 1.20
Conflict of interest declarations: could a 'traffic light' system work? Addiction (2009) 0.94
Disclosure in the best interests of science? Or moral crusade? Addiction (2009) 0.91
Disclosing conflicts of interest: common standards in uncommon contexts. Addiction (2009) 0.91
Supporting the need for rigorous enforceable disclosure policies for scientific journals. Addiction (2009) 0.90
Scientific journals and conflict of interest disclosure: what progress has been made? Environ Health (2015) 0.87
Has industry funding biased studies of the protective effects of alcohol on cardiovascular disease? A preliminary investigation of prospective cohort studies. Drug Alcohol Rev (2014) 0.81
EASE Guidelines for Authors and Translators of Scientific Articles to be Published in English. Acta Inform Med (2014) 0.78
Addiction industry studies: understanding how proconsumption influences block effective interventions. Am J Public Health (2013) 0.75
Towards a common standard for conflict of interest disclosure. Addiction (2009) 0.75
Re: A common standard for conflict of interest disclosure in addiction journals. Addiction (2010) 0.75
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Expanding access to testicular tissue cryopreservation: an analysis by analogy. Am J Bioeth (2013) 7.01
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
An invitation to an alcohol industry lobby to help decide public funding of alcohol research and professional training: a decision that should be reversed. Addiction (2004) 5.61
Direct to confusion: lessons learned from marketing BRCA testing. Am J Bioeth (2008) 4.56
The alcohol industry and public interest science. Addiction (2009) 4.08
Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). Addiction (2008) 3.98
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
The integrity of the science base: a test case. Addiction (2005) 3.40
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Bioethics consultation in the private sector. Hastings Cent Rep (2002) 3.01
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Appropriate use of artificial nutrition and hydration--fundamental principles and recommendations. N Engl J Med (2005) 2.96
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2009) 2.82
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) (2011) 2.26
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Engineered whole organs and complex tissues. Lancet (2012) 2.08
Neurotalk: improving the communication of neuroscience research. Nat Rev Neurosci (2009) 1.98
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction (2002) 1.94
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91
The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer (2013) 1.76
Industrial epidemics, public health advocacy and the alcohol industry: lessons from other fields. Addiction (2007) 1.70
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
The trouble with alcohol abuse: what are we trying to measure, diagnose, count and prevent? Addiction (2008) 1.63
Changing the focus: the case for recognizing and treating cannabis use disorders. Addiction (2002) 1.62
Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2003) 1.52
The word "cancer": how language can corrupt thought. BMJ (2013) 1.51
Efficacy and the strength of evidence of U.S. alcohol control policies. Am J Prev Med (2013) 1.47
Denying autonomy in order to create it: the paradox of forcing treatment upon addicts. Addiction (2008) 1.47
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
Tackling alcohol misuse in the UK. BMJ (2008) 1.45
A population approach to precision medicine. Am J Prev Med (2012) 1.44
Postmortem parenthood and the need for a protocol with posthumous sperm procurement. Fertil Steril (2003) 1.43
Beyond alcoholism: identifying older, at-risk drinkers in primary care. J Stud Alcohol (2002) 1.42
Longer-term outcomes after kidney transplantation from seronegative deceased donors at increased risk for blood-borne viral infection. Transplantation (2011) 1.42
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40
Diagnosis of alcohol dependence in epidemiological surveys: an epidemic of youthful alcohol dependence or a case of measurement error? Addiction (2006) 1.40
Organs.com: new commercially brokered organ transfers raise questions. Hastings Cent Rep (2005) 1.40
Standardizing terminology in addiction science: to achieve the impossible dream. Addiction (2007) 1.39
The costs of screening and brief intervention for risky alcohol use. J Stud Alcohol (2003) 1.32
National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry (2002) 1.29
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics (2004) 1.27
Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol (2002) 1.27
Biomarkers, subgroup evaluation, and clinical trial design. Discov Med (2012) 1.21
Health of the nation--coverage for all Americans. N Engl J Med (2008) 1.18
National Children's Study: update in 2010. Mt Sinai J Med (2011) 1.17
Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats. BMC Cancer (2009) 1.15
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates. Biostatistics (2005) 1.15
Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med (2012) 1.14
Alcohol drinking patterns and health care utilization in a managed care organization. Health Serv Res (2004) 1.14
Alcohol and alcohol-related harm in China: policy changes needed. Bull World Health Organ (2013) 1.14
Another mirror shattered? Tobacco industry involvement suspected in a book which claims that nicotine is not addictive. Addiction (2002) 1.13
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int (2007) 1.13
Treatment process, alliance and outcome in brief versus extended treatments for marijuana dependence. Addiction (2010) 1.12
The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"? BMC Med Res Methodol (2004) 1.11
Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer (2007) 1.10
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Malaria initiative. Lancet (2004) 1.09
Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. Cancer (2005) 1.08
Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis. Stat Methods Med Res (2005) 1.08
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol (2002) 1.08
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology (2006) 1.07
Cancer screening in theory and in practice. J Clin Oncol (2005) 1.06
Incentive models to increase living kidney donation: encouraging without coercing. Am J Transplant (2005) 1.06
Employee designation and health care worker support of an influenza vaccine mandate at a large pediatric tertiary care hospital. Vaccine (2011) 1.03
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2006) 1.01
Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomes. BMC Med Res Methodol (2003) 0.99
The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst (2013) 0.98
Estimating the cumulative risk of false positive cancer screenings. BMC Med Res Methodol (2003) 0.98
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Med Res Methodol (2003) 0.98
5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int (2010) 0.97
Deep brain stimulation of the nucleus accumbens for the treatment of addiction. Ann N Y Acad Sci (2012) 0.96
The ethics and politics of small sacrifices in stem cell research. Kennedy Inst Ethics J (1999) 0.95
Effects of cautionary messages and vulnerability factors on viewers' perceptions of alcohol advertisements. J Stud Alcohol (2005) 0.94
Ethics, evolution, and the milk of human kindness. Hastings Cent Rep (1976) 0.93
Right-to-Try Laws: Hope, Hype, and Unintended Consequences. Ann Intern Med (2015) 0.92
Defining mental illnesses: can values and objectivity get along? BMC Psychiatry (2013) 0.91
The Chinese translations of Alcohol Use Disorders Identification Test (AUDIT) in China: a systematic review. Alcohol Alcohol (2011) 0.91
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen (2011) 0.89